Posted in | News | Nanomedicine | Nanobusiness

The Journal of Spinal Disorders & Techniques Highlights nanOss® Clinical Data Results

RTI Surgical Inc.™ (RTI), a leading global surgical implant company, announced that The Journal of Spinal Disorders & Techniques published a study online highlighting nanOss® clinical data results. NanOss is an advanced bone graft substitute that is composed of nano-structured hydroxyapatite granules and an open structured engineered collagen carrier.

The Journal of Spinal Disorders & Techniques highlights peer-reviewed original articles on diagnosis, management and surgery for spinal issues. The study, published by the Journal online, is titled Use of Nanocrystalline Hydroxyapatite with Autologous BMA and Local Bone in the Lumbar Spine: A Retrospective CT Analysis of Posterolateral Fusion Results. Stephen E. Robbins, MD, orthopedic surgeon at Milwaukee Spinal Specialists, was the lead author on the study.

The study was comprised of a retrospective, multi-center, medical record review and independent analysis of CT scans that were performed in 46 patients. The 12-month postoperative CT scans determined radiographic arthrodesis rates after one-, two- or three-segment instrumented posterolateral fusions using autograft, BMA and a nanocrystalline hydroxyapatite bone void filler. The results showed that 94 percent of vertebral segments treated exhibited bilateral or unilateral posterolateral bridging bone.

NanOss’s multidimensional porosity is similar to human cancellous bone and provides a scaffold for the in-growth of new bone. It incorporates into the patient’s own newly-formed bone resulting in a fusion mass – the ultimate goal of any bone graft.

“The use of iliac crest autograft carries significant risk and creates a painful, secondary surgery site,” said Brian K. Hutchison, president and chief executive officer of RTI Surgical. “NanOss gives surgeons another bone growth option that has demonstrated equivalent fusion rates in the lumbar spine and provides an alternative for their patients. This study supports what we have heard from surgeons since the introduction of this product.”

Source: http://www.rtix.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.